Drug intelligence / Profile preview

human normal immunoglobulin (CSL Limited)

Development stage
Approved
Lead developer
Aalborg University Hospital
Modality
Antibody-Based Therapeutics
Administration
Intravenous
01

Overview

Human normal immunoglobulin is a plasma-derived, polyvalent human IgG preparation administered intravenously; the Aalborg recurrent pregnancy loss study used the 10% IVIg product **Privigen**. It contains a broad spectrum of intact IgG antibodies and has pleiotropic immunomodulatory activity, including antibody-mediated neutralisation and opsonisation, rather than a single defined molecular target. At Aalborg University Hospital, Privigen was investigated with oral prednisolone in a completed randomised, double-blind, placebo-controlled phase 2 trial for unexplained recurrent pregnancy loss after assisted reproductive technology; the IVIg component was administered around embryo transfer and through early pregnancy. ([cdek.pharmacy.purdue.edu](https://cdek.pharmacy.purdue.edu/trial/NCT04701034/))

Brand names
Privigen
Other names
human intravenous immunoglobulinimmunoglobulin intravenous humanintravenous immunoglobulinIVIg
02

Targets

FcγR (Low affinity immunoglobulin gamma Fc region receptor II-c)C3GR (Glucocorticoid receptor)

Beyond the preview

Go deeper on human normal immunoglobulin (CSL Limited).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human normal immunoglobulin (CSL Limited).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call